Bengt Fellström, Faiez Zannad, Roland Schmieder, Hallvard Holdaas, Alan Jardine, Helen Rose, Wim Wilpshaar
Abstract
Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased risk of cardiovascular mortality in this population. In contrast to patients with normal renal function, the benefits of modifying lipid levels on cardiovascular outcomes in patients with ESRD on haemodialysis have yet to be confirmed in large prospective randomised trials. A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events (AURORA) will be the first large-scale international trial to assess the effects of statin therapy on cardiovascular morbidity and mortality in ESRD patients on chronic haemodialysis.
Pharmacology, Toxicology and Pharmaceutical Science
2
5%
Biochemistry, Genetics and Molecular Biology
1
2%
Nursing and Health Professions
1
2%
Other
4
10%
Unknown
15
36%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 January 2010.
All research outputs
#8,783,469
of 25,986,827 outputs
Outputs from Current Controlled Trials in Cardiovascular Medicine
#1
of 1 outputs
Outputs of similar age
#25,296
of 71,209 outputs
Outputs of similar age from Current Controlled Trials in Cardiovascular Medicine
#2
of 3 outputs
Altmetric has tracked 25,986,827 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1 research outputs from this source. They receive a mean Attention Score of 3.0. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 71,209 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.
